Results 41 to 50 of about 984 (179)

The last decade\u27s experience of management of central neurocytomas: Treatment strategies and new options [PDF]

, 2021
Background: The purpose of the presented work is to evaluate the last decade\u27s experience in surgical management of central neurocytoma (CN) and elucidate on the treatment strategies and new options.
Siomin, Vitaly
core   +1 more source

Rosette-forming glioneuronal tumor: a pineal region case with IDH1 and IDH2 mutation analyses and literature review of 43 cases [PDF]

, 2010
Rosette-forming glioneuronal tumor (RGNT) of the fourth ventricle is a mixed glio-neuronal neoplasm recently codified by the World Health Organization WHO Classification of Central Nervous System (CNS) Tumors (2007). To date, 43 cases have been described
Orestes E. Solis, Rupal I. Mehta, Albert Lai, Rashi I. Mehta, Lama O. Farchoukh, Richard M. Green, Jerry C. Cheng, Sathima Natarajan, Harry V. Vinters, Timothy Cloughesy, William H. Yong   +10 more
core   +2 more sources

The 2021 WHO Classification of Tumors of the Central Nervous System: a summary [PDF]

, 2021
The fifth edition of the WHO Classification of Tumors of the Central Nervous System (CNS), published in 2021, is the sixth version of the international standard for the classification of brain and spinal cord tumors.
Brat, Daniel J, Cree, Ian A, Ellison, David W, Figarella-Branger, Dominique, Hawkins, Cynthia, Louis, David N, Ng, HK, Perry, Arie, Pfister, Stefan M, Reifenberger, Guido, Soffietti, Riccardo, von Deimling, Andreas, Wesseling, Pieter   +12 more
core   +3 more sources

중심성 신경세포종의 종양발생기전 [PDF]

, 2022
학위논문(박사) -- 서울대학교대학원 : 의과대학 의학과, 2022. 8. 박철기.배경: 중심성 신경세포종은 일반적으로 젊은 성인에게서 많이 발생하는 중추신경계에서 가장 드물게 발생하는 종양 중 하나이다. 중심성 신경세포종의 발생과 분화에 관련하여 통합적인 분자 및 유전자 특성 연구는 현재까지 부재하며 종양발생기전은 확실하게 밝혀지지 않았다.
탐린
core  

Roles and Impacts of Integrative Medical Interventions in Central Nervous System Tumor Treatment: Multi‐Technology Convergence and the Paradigm Shift Toward Functional Reconstruction

CNS Neuroscience &Therapeutics, Volume 31, Issue 7, July 2025.
Multi‐technology interventions (non‐invasive neuromodulation, AI, 3D organoids) for CNS tumor treatment shift from monotherapy to functional reconstruction. They address BBB restriction, tumor heterogeneity, and immune suppression via biological–psychological–technological convergence, enabling precision oncology through dynamic monitoring and ...
Junda Lai, Ketao Liu, Yuhua Lin, Zhonglin Chen, Xianglun Ji, Junkai Wen   +5 more
wiley   +1 more source

Diffuse Glioneuronal tumour with Oligodendroglioma‐like features and Nuclear Clusters (DGONC) – a molecularly‐defined glioneuronal CNS tumour class displaying recurrent monosomy 14 [PDF]

, 2019
Aims: DNA methylation-based central nervous system (CNS) tumour classification has identified numerous molecularly distinct tumour types, and clinically relevant subgroups among known CNS tumour entities that were previously thought to represent ...
Aronica, E., Deckert, M., Deimling, A., Deng, M. Y., Dunham, C., Ebinger, M., Ecker, J., Ellison, D. W., Figarella‐Branger, D., Giangaspero, F., Gottardo, N., Haberler, C., Hartmann, C., Herold-Mende, C., Hoff, K., Jabado, N., Jones, D. T. W., Keyvani, K., Kool, M., Korshunov, A., Lauten, M., Milde, T., Pfister, S. M., Pietsch, T., Preusser, M., Sahm, F., Schittenhelm, J., Schuhmann, M. U., Schüller, U., Sill, M., Snuderl, M., Staszewski, O., Stichel, D., Sturm, D., Wesseling, P., Wick, W., Witt, H., Witt, O., Wittmann, A.   +38 more
core   +3 more sources

Posterior pituitary tumors and other rare entities involving the pituitary gland

Brain Pathology, Volume 35, Issue 1, January 2025.
Abstract Non‐neuroendocrine tumors account for around 10% of all primary neoplasms of the sella. If meningiomas, craniopharyngiomas, and germ cell tumors are excluded, the remaining lesions include a broad spectrum of uncommon, benign, and aggressive, often diagnostically challenging lesions.
Federico Roncaroli, Caterina Giannini
wiley   +1 more source

Exploring the interdependencies of research funders in the UK [PDF]

, 2014
Investment in medical research is vital to the continuing improvement of the UK's health and wealth. It is through research that we expand our understanding of disease and develop new treatments for patients.
Crane, P, Farrell, C, Garau, M, Grassano, N, Hernandez-Villafuerte, K, Hopkins, M M, Hutton, J, Lang, F, Mawer, A, Pateman, C, Rotolo, D, Shah, K, Sharp, T, Sussex, J   +13 more
core   +1 more source

A Novel Germline MUTYH Mutation (p.W156∗) in High‐Grade Astrocytoma, IDH Mutant

Human Mutation, Volume 2025, Issue 1, 2025.
Germline mutations in the DNA repair gene E. coli MutY homolog (MUTYH) are established predisposing factors for colorectal polyposis, colorectal carcinoma, and various extracolonic malignancies. Nevertheless, the association between MUTYH mutations and central nervous system (CNS) tumorigenesis remains poorly characterized.
Lulu Zhang, Shaoyan Xi, Lei Yuan, Ziteng Li, Xiaoyun Liu, Jiamei Gu, Shuo Li, Liyun Huang, Wanming Hu, Lingyi Fu, Aziz ur Rehman Aziz   +10 more
wiley   +1 more source

Successful Treatment of MDR Acinetobacter baumannii Meningitis in a Young Adult Patient With Intraventricular and Intravenous Polymyxin B‐Tigecycline Based Combinations: A Case Report

Clinical Case Reports, Volume 12, Issue 11, November 2024.
ABSTRACT Multiple drug resistance to Acinetobacter baumannii infection treatment is a great challenge for neuro‐intensivists due to poor drug penetration through the blood–brain barrier (BBB). Fortunately, the intraventricular administration of polymyxin‐B and tigecycline seems to be effective; there are few case reports demonstrating the effectiveness
Md Abdur Rahim, Himel Kumar Biswas, Md Abdul Kader Zilani, Rama Biswas, Sirazul Haque Ershad   +4 more
wiley   +1 more source